DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tequin (Gatifloxacin) - Published Studies

 
 



Tequin Related Published Studies

Well-designed clinical trials related to Tequin (Gatifloxacin)

Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. [2011.09]

A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. [2011.08]

Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. [2011.06]

Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. [2011.06]

A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. [2009.08]

Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery. [2008.05]

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. [2008.03]

An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. [2007.06.27]

The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy. [2007.04]

Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. [2006.04]

Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. [2006.02]

Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. [2006.02]

Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. [2005.11]

The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. [2005.07]

A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. [2005.06]

Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. [2005.04]

Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children. [2005.04]

A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis. [2005.03]

Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. [2005.03]

Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. [2005.01]

A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. [2004.11]

A study to determine the pharmacokinetics of gatifloxacin following a single oral dose. [2004.09]

Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. [2004.06]

Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia. [2004.06]

A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. [2004.05]

Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. [2004.03]

Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. [2004.03]

Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia. [2004.02]

Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. [2003.05]

Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. [2003.05]

Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis. [2003.03]

Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers. [2003.01]

Minimal interaction between gatifloxacin and oxycodone. [2002.08]

Oral bioavailability of gatifloxacin in healthy volunteers under fasting and fed conditions. [2002.07]

A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis. [2002.02]

A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. [2002.02]

Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. [2001.08]

Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. [2001.05]

Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial. [2001.03]

Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. [2001.01]

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. [2000.10]

Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. [2000.06]

Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults. [2000.06]

Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. [1999.05]

Well-designed clinical trials possibly related to Tequin (Gatifloxacin)

Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). [2011.10.05]

Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. [2011.09]

Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. [2011.07]

Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. [2011.07]

Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial. [2011.02]

Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial. [2011]

Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections. [2010.12]

Comparison of the effects of fourth-generation fluoroquinolones on epithelial healing after photorefractive keratectomy. [2010.11]

Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers. [2010.07]

Changes in drug susceptibility and the quinolone-resistance determining region of Staphylococcus epidermidis after administration of fluoroquinolones. [2009.11]

Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK. [2009.02]

A comparison of fluoroquinolone penetration into human conjunctival tissue. [2008.12]

Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. [2007.11]

Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. [2007.06.19]

Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. [2006.10]

Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. [2006.08]

Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. [2006.06]

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. [2005.05.17]

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. [2005.04.21]

C-reactive protein levels and outcomes after statin therapy. [2005.01.06]

Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. [2004.04]

Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. [2002.03]

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. [2001.10]

Other research related to Tequin (Gatifloxacin)

Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. [2013]

Effect of gatifloxacin against Mycoplasma genitalium-related urethritis: an open clinical trial. [2011.08]

Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. [2011.01]

Gatifloxacine-loaded PLGA and beta-tricalcium phosphate composite for treating osteomyelitis. [2011]

Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK. [2011]

A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. [2011]

Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. [2011]

Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. [2010.11]

Gatifloxacin-induced histamine release and hyperglycemia in rats. [2010.10.25]

Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits. [2010.10]

Determination of drug concentration in aqueous humor of cataract patients administered gatifloxacin ophthalmic gel. [2010.08.05]

[Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes]. [2010.06]

Clinicopathological aspect of dysglycemia in naive and diabetic rats induced by the fluoroquinolone antibacterial gatifloxacin. [2010.05]

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. [2010.04.26]

Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. [2010.04.05]

Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. [2010.04]

Atypical mycobacterium keratitis associated with penetrating keratoplasty: case report of successful therapy with topical gatifloxacin 0.3%. [2010.04]

Determination of drug concentration in aqueous humor of cataract patients administered gatifloxacin ophthalmic gel. [2010]

Effect of dosing interval on the efficacy of topical ophthalmic gatifloxacin against Enterococcus faecalis in an in vitro pharmacokinetic model simulating the local eye compartment. [2009.12]

[Human aqueous humor levels of levofloxacin 0.5%, gatifloxacin 0.3% and levofloxacin 0.3% ophthalmic solution after topical dosing.] [2009.11]

Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection. [2009.11]

Safety of intracameral injection of gatifloxacin, levofloxacin on corneal endothelial structure and viability. [2009.10]

Evaluation of vitreous levels of gatifloxacin after systemic administration in inflamed and non-inflamed eyes. [2009.09]

Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains. [2009.08]

Clinical efficacy of oral administration of 200 mg gatifloxacin once daily for 3 days for the treatment of patients with uncomplicated cystitis. [2009.04]

Gatifloxacin-induced severe hyperglycaemia and ketoacidosis in a non-diabetic renal transplant recipient. [2009.02]

Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin. [2009]

Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. [2008.12]

Comparison of one-day versus one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora. [2008.11]

Successful treatment of post-neurosurgical intracranial Mycoplasma hominis infection using gatifloxacin. [2008.10]

An evaluation of the effects of gatifloxacin on glucose homeostasis. [2008.10]

The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility. [2008.08]

Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis. [2008.08]

Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains. [2008.08]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017